GT Biopharma Receives Institutional Review Board Approval to Proceed With in Human FDA Phase 1 Clinical Trial

TAMPA, Florida, April 8, 2019 /CNW/ –GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology biotechnology company focused on innovative treatments based on

Read more

Todos and Amarantus Announce Completion of LymPro PET 1 Study by Leipzig University for Alzheimer’s Blood Diagnostic LymPro Test 2.0

REHOVOT, Israel and NEW YORK, April 08, 2019 (GLOBE NEWSWIRE) — Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics

Read more

Interview: CEO Allen Davidoff of XORTX Therapeutics Inc.(OTCQB: XRTXF)

CEO Allen Davidoff of XORTX Therapeutics Inc., talks about their focus of developing therapies for kidney disease, diabetic nephropathy, and cardiovascular disease.

Read more

CytoDyn and Samsung BioLogics Enter into Agreement to Manufacture $1 Billion Worth of Leronlimab (PRO 140) to Meet Expected Demand for Future Revenues Post-Approval

VANCOUVER, Washington, April 02, 2019 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company

Read more

ProMIS Neurosciences to Present Data for Potential Best-in-Class Antibody Candidates for Parkinson’s Disease at AD/PD™ 2019 Conference

Canada NewsWire TORONTO and CAMBRIDGE, MA, March 19, 2019 Selected for podium presentation: novel antibody candidates bind only the toxic

Read more

CytoDyn Reaches Historical Milestone, Submits First of Three Sections of BLA to FDA for Leronlimab (PRO 140) as a Combination Therapy for HIV

VANCOUVER, Washington, March 18, 2019 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company

Read more

Sunniva Launches First Three Cannabis Brands in California

VANCOUVER, BC / ACCESSWIRE / March 13, 2019 / Sunniva Inc. (“Sunniva”, the “Company”, “we”, “our” or “us”) (CSE: SNN)

Read more

FDA Grants Rolling Review for CytoDyn’s Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

VANCOUVER, Washington, March 04, 2019 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), a late stage biotechnology company developing leronlimab (PRO 140),

Read more